CPT® Code 90673

1. Indications

The Influenza virus vaccine, trivalent (RIV3), is indicated for the prevention of influenza caused by the strains included in the vaccine formulation. The vaccine is particularly recommended for individuals who are at higher risk of developing complications from influenza, including but not limited to:

• High-Risk Populations: Individuals with chronic health conditions, such as asthma, diabetes, or heart disease, who may experience severe illness if infected with the influenza virus.
• Older Adults: Seniors aged 65 years and older, who are more susceptible to influenza-related complications.
• Healthcare Workers: Those who are in close contact with patients, particularly in healthcare settings, to help prevent the spread of influenza.
• Pregnant Women: Pregnant individuals, as they are at increased risk for severe illness from influenza and can also pass immunity to their newborns.

2. Procedure

The administration of the Influenza virus vaccine, trivalent (RIV3), involves several key procedural steps to ensure proper delivery and effectiveness of the vaccine. Each step is critical to the overall success of the vaccination process.

• Step 1: Preparation of the Vaccine The vaccine should be prepared according to the manufacturer's guidelines. This includes checking the expiration date, ensuring the vaccine is stored at the correct temperature, and gently swirling the vial to mix the contents without shaking, which could damage the vaccine.
• Step 2: Patient Assessment Prior to administration, a thorough assessment of the patient should be conducted. This includes reviewing the patient's medical history, checking for any contraindications to the vaccine, and obtaining informed consent. It is essential to ensure that the patient is not allergic to any components of the vaccine.
• Step 3: Administration of the Vaccine The vaccine is administered via intramuscular injection, typically in the deltoid muscle of the upper arm for adults and older children, or in the anterolateral thigh for infants and young children. The injection site should be cleaned with an alcohol swab before administration to minimize the risk of infection.
• Step 4: Post-Administration Monitoring After the vaccine is administered, the patient should be monitored for a short period to observe for any immediate adverse reactions. This is particularly important for individuals who may have a history of allergic reactions to vaccines.

3. Post-Procedure

Following the administration of the Influenza virus vaccine, trivalent (RIV3), patients are typically advised to remain in the healthcare setting for a brief observation period, usually around 15 minutes, to ensure they do not experience any immediate adverse effects. Common post-vaccination care includes advising patients about potential mild side effects, such as soreness at the injection site, low-grade fever, or fatigue, which are generally self-limiting. Patients should be informed to seek medical attention if they experience any severe allergic reactions, such as difficulty breathing or swelling of the face and throat. Additionally, patients may be encouraged to report any unusual symptoms or side effects to their healthcare provider. It is also important to remind patients that the vaccine does not provide immediate immunity and that it typically takes about two weeks for the body to develop protection against the influenza virus after vaccination.